Cornerstone Planning Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Cornerstone Planning Group’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$334	Hold	167	–	–	﹤0.01%	1728
2025 Q4	$433	Buy	167 +100	+149%	+$479	﹤0.01%	1536
2025 Q3	$5.29K	Buy	67 +59	+738%	+$356	﹤0.01%	934
2025 Q2	$850	Sell	8 -159	-95%	-$1.28K	﹤0.01%	1156
2025 Q1	$1.29K	Hold	167	–	–	﹤0.01%	1079
2024 Q4	$2.81K	Hold	167	–	–	﹤0.01%	702
2024 Q3	$6.49K	Hold	167	–	–	﹤0.01%	515
2024 Q2	$6.49K	Hold	167	–	–	﹤0.01%	519
2024 Q1	$7.26K	Hold	167	–	–	﹤0.01%	461
2023 Q4	$12.8K	Buy	+167	New	+$12.6K	﹤0.01%	388

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Cornerstone Planning Group's ACXP Position: Q1 2026 in Review

Cornerstone Planning Group held its Acurx Pharmaceuticals (ACXP) position steady in Q1 2026 at 167 shares worth $334. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Cornerstone Planning Group first reported a position in ACXP in Q4 2023 and has held it in 10 quarters since. The position peaked at $12.8K in Q4 2023. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Cornerstone Planning Group held 167 shares of Acurx Pharmaceuticals worth $334 as of Q1 2026.
Cornerstone Planning Group left its Acurx Pharmaceuticals share count unchanged in Q1 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q1 2026, its #1728 holding.
Cornerstone Planning Group first reported a position in Acurx Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Cornerstone Planning Group's Acurx Pharmaceuticals position peaked at $12.8K in Q4 2023.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Cornerstone Planning Group's 13F filing for Q1 2026, filed 6 May 2026.